Effect of MUC1 siRNA on Drug Resistance of Gastric Cancer Cells to Trastuzumab

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 127-131

  Deng, Min ^a,b   Jing, Da Dao ^a   Meng, Xiang Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Department of Gastroenterolgy   (China)

Author keywords

Drug resistance; Gastric cancer; HER2; Mucin1; siRNA; Trastuzumab

Indexed keywords

EID: 84877122771     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.127     Document Type: Article

References (19)

1. Bang Y, Van Cutsem E, Feyereislova A, et al (2010). ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97.
2. Citri A, Kochupurakkal BS, Yarden Y (2004). The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle, 3, 51-60.
3. Fessler SP, Wotkowicz MT, Mahanta SK, et al (2009). MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat, 118, 113-24.
4. Gerlinger M, Rowan AJ, Horswell S, et al (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 366, 883-92.
5. Hikita ST, Kosik KS, Clegg DO, et al (2008). MUC1* mediates the growth of human pluripotent stem cells. PLoS One, 3, e3312.
6. Lang SA, Klein D, Moser C, et al (2007). Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther, 6, 1123-32.
7. Lapointe J, Li C, Higgins JP, et al (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A, 101, 811.
8. L'Esperance S, Popa I, Bachvarova M, et al (2006). Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol, 29, 5-24.
9. Mahanta S, Fessler SP, Park J, et al (2008). A minimal fragment of MUC1 mediates growth of cancer cells. PLoS One, 3, e2054.
10. Nahta R, Esteva FJ (2007). Trastuzumab: triumphs and tribulations. Oncogene, 26, 3637-43.
11. Price, Schiavi SA, Jepson S, Li P, et al (2002). Rat Muc4 (sialomucin complex) reduces binding of anti. ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer, 99, 783-791.
12. Raina D, Kharbanda S, Kufe D (2004). The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem, 279, 20607-12.
13. Ren J, Agata N, Chen D, et al (2004). Human MUC1 carcinomaassociated protein confers resistance to genotoxic anticancer agents. Cancer Cell, 5, 163-75.
14. Siragusa M, Zerilli M, Iovino F, et al (2007). MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res, 67, 5522.
15. Valabrega G, Montemurro F, Aglietta M (2007). Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol, 18, 977-84.
16. Velho S, Oliveira C, Ferreira A, et al (2005). The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer, 41, 1649-54.
17. Vogel CL, Cobleigh MA, Tripathy D, et al (2001). Firstline Herceptin monotherapy in metastatic breast cancer. Oncology, 2, 37-42.
18. Yang J, Luo H, Li Y, et al (2012). Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys, 62, 221-28.
19. Yin L, Li Y, Ren J, et al (2003). Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem, 278, 35458-64.